Shares of MyoKardia (NASDAQ:MYOK) stock are soaring on Monday after a major deal with another pharmaceutical company.
Bristol Myers Squibb (NYSE:BMY) announced that it is acquiring MyoKardia for $13.1 billion, or $225 per share, in cash. MyoKardia is a biopharmaceutical company that discovers and develops specific therapies in order to treat serious cardiovascular diseases.
That said, the major asset in this acquisition is mavacamten. It is a possible top-of-the-line cardiovascular medicine for treating people with obstructive hypertrophic cardiomyopathy.
Tassos Gianakakos, CEO of MyoKardia, had this to say about the deal with Bristol Myers Squibb:
“Bristol Myers Squibb shares our vision for transforming the treatment of cardiovascular disease. They value our team and the potential of our platform and,